Open access
Open access
Powered by Google Translator Translator

Dermatology

Study Supports Link Between COVID-19 and ‘COVID Toes’

3 Jul, 2020 | 08:34h | UTC

SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultraestructural study of 7 paediatric cases – British Journal of Dermatology

News Release: Study supports link between COVID-19 and ‘COVID Toes’ – Wiley

 


Randomized Trial: Atezolizumab, Vemurafenib, and Cobimetinib for Advanced BRAFV600 Mutation-positive Melanoma

16 Jun, 2020 | 07:48h | UTC

Atezolizumab, vemurafenib, and cobimetinib as first-line treatment for unresectable advanced BRAFV600 mutation-positive melanoma (IMspire150): primary analysis of the randomised, double-blind, placebo-controlled, phase 3 trial – The Lancet

 


Cohort Study: Fexofenadine use During Pregnancy Does Not Appear to Be Associated with Increased Risk of Adverse Fetal Outcomes

3 Jun, 2020 | 03:31h | UTC

Association Between Fexofenadine Use During Pregnancy and Fetal Outcomes – JAMA Pediatrics (free for a limited period)

 


German Guidelines for the Diagnosis and Treatment of Perianal Dermatitis

1 Jun, 2020 | 03:49h | UTC

German S1 guidelines for the diagnosis and treatment of perianal dermatitis (anal eczema) – Journal of the German Society of Dermatology

 


EULAR Recommendations for the Management of Psoriatic Arthritis

28 May, 2020 | 09:31h | UTC

EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update – Annals of Rheumatic Diseases

Editorial: EULAR PsA management recommendations 2019: can the recommendations be improved?

Commentary: EULAR releases recommendations for PsA management – Medicine Matters

 


Study: Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients

26 May, 2020 | 09:43h | UTC

Androgenetic Alopecia Present in the Majority of Hospitalized COVID-19 Patients – the “Gabrin sign” – Journal of the American Academy of Dermatology

 


Classification of the Cutaneous Manifestations of COVID‐19 with 375 Illustrative Cases

1 May, 2020 | 03:43h | UTC

Classification of the cutaneous manifestations of COVID‐19: a rapid prospective nationwide consensus study in Spain with 375 cases – British Journal of Dermatology

Related: Journal articles on coronavirus with relevance for skin diseases and dermatology – Centre of Evidence Based Dermatology, University of Nottingham AND Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak – Journal of the American Academy of Dermatology

Great atlas with the different cutaneous manifestations of Covid-19.

 


Case Series: Characterization of Ischemic Cutaneous Lesions Associated with Covid-19

29 Apr, 2020 | 05:14h | UTC

Characterization of acute acro-ischemic lesions in non-hospitalized patients: a case series of 132 patients during the COVID-19 outbreak – Journal of the American Academy of Dermatology

See also: Journal articles on coronavirus with relevance for skin diseases and dermatology – Centre of Evidence Based Dermatology, University of Nottingham AND From ‘COVID Toes’ to Hives, These Are the Skin Conditions Dermatologists Think Could Be Signs of Coronavirus – TIME

 


ASCO Guideline: Systemic Therapy for Melanoma

3 Apr, 2020 | 03:57h | UTC

Systemic Therapy for Melanoma: ASCO Guideline – Journal of Clinical Oncology

 


Randomized Trial: Treatment of Advanced AIDS-associated Kaposi Sarcoma in Resource-limited Settings

8 Mar, 2020 | 20:16h | UTC

Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial – The Lancet (free)

 


FDA Safety Alert: Montelukast May Cause Serious Mental Health Side Effects

6 Mar, 2020 | 10:22h | UTC

FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis – U.S. Food & Drug Administration (free)

Commentary: Montelukast to Get Boxed Warning – NEJM Journal Watch (free)

 


NICE Guideline: Antimicrobial Prescribing Guidance for Impetigo

27 Feb, 2020 | 08:45h | UTC

Impetigo: antimicrobial prescribing – National Institute for Health and Care Excellence (free)

Commentary: Antiseptic not antibiotic should be considered for impetigo – PharmaField (free)

Related: NICE Antimicrobial prescribing guidelines (resource covering many common conditions) AND NICE Summary of antimicrobial prescribing guidance – managing common infections (free PDF)

 


Meta-analysis: Prevalence, Incidence, and Risk of Cancer in Patients with Psoriasis and Psoriatic Arthritis

25 Feb, 2020 | 05:55h | UTC

Prevalence, Incidence, and Risk of Cancer in Patients With Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis – JAMA Dermatology (free for a limited period)

 


Randomized Trial: No Evidence That Daily Emollient During the First Year of Life Prevents Eczema

21 Feb, 2020 | 07:28h | UTC

Daily emollient during infancy for prevention of eczema: the BEEP randomised controlled trial – The Lancet (free)

Related Study: Skin emollient and early complementary feeding to prevent infant atopic dermatitis (PreventADALL): a factorial, multicentre, cluster-randomised trial – The Lancet (link to abstract – $ for full-text)

Commentaries: Emollients for prevention of atopic dermatitis in infancy – The Lancet (free) AND Daily moisturizer does not prevent eczema according to new research – News Medical (free)

 

Related Commentary on Twitter

 


Management of Dermatologic Adverse Events from Cancer Therapies

18 Feb, 2020 | 08:05h | UTC

Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel – Arquivos Brasileiros de Dermatologia (free)

 


Study: Poor Performance of Apps Assessing Skin Cancer Risk

13 Feb, 2020 | 07:56h | UTC

Algorithm based smartphone apps to assess risk of skin cancer in adults: systematic review of diagnostic accuracy studies – The BMJ (free)

Editorial: The poor performance of apps assessing skin cancer risk (free)

Commentaries: Skin cancer diagnosis apps are unreliable and poorly regulated, study shows – eCancer News (free) AND Phone apps unreliable for detecting all cases of skin cancer – OnMedica (free)

 


NICE Guideline: Antimicrobial Prescribing for Leg Ulcer Infection

12 Feb, 2020 | 07:35h | UTC

Leg ulcer infection: antimicrobial prescribing – National Institute for Health and Care Excellence (free)

Related: NICE Antimicrobial prescribing guidelines (resource covering many common conditions) AND NICE Summary of antimicrobial prescribing guidance – managing common infections (free PDF)

 

Related Commentary on Twitter

 


Systematic Review: Topical and Device‐based Treatments for Fungal Infections of the Toenails

26 Jan, 2020 | 22:39h | UTC

Topical and device‐based treatments for fungal infections of the toenails – Cochrane Library (free)

Summary: Are topical and device-based treatments effective in people with fungal infections of the toenails? – Cochrane Library (free)

 


Randomized Trial: Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients

23 Jan, 2020 | 09:45h | UTC

Effect of Sunscreen Application on Plasma Concentration of Sunscreen Active Ingredients: A Randomized Clinical Trial – JAMA (free for a limited period)

Editorial: Systemic Absorption of Sunscreen: Balancing Benefits With Unknown Harms (free for a limited period)

Commentaries: Expert reaction to study looking at sunscreen ingredients and absorption into the blood – Science Media Centre (free) AND All Major Sunscreen Ingredients Absorbed Through the Skin – MedicalResearch.com (free) AND Sunscreen ingredients really do seep into the blood. Is that bad? – Reuters (free)

 


Systematic Review: Interventions for Chronic Palmoplantar Pustulosis

22 Jan, 2020 | 09:21h | UTC

Interventions for chronic palmoplantar pustulosis – Cochrane Library (free)

Summary: Treating long-term palmoplantar pustulosis (pustules on the hands and feet) – Cochrane Library (free)

 


Recommendations for the Management of Psoriatic Arthritis in Resource-poor Settings

19 Jan, 2020 | 21:01h | UTC

International league of associations for rheumatology recommendations for the management of psoriatic arthritis in resource-poor settings – Clinical Rheumatology (free)

 


[Abstract Only] Randomized Trial: Different Doses of Adjuvant Ipilimumab vs. High-Dose Interferon Alfa-2b in Patients with Resected High-Risk Melanoma

19 Jan, 2020 | 20:40h | UTC

Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma – The ASCO Post (free)

Original Study: Phase III Study of Adjuvant Ipilimumab (3 or 10 mg/kg) Versus High-Dose Interferon Alfa-2b for Resected High-Risk Melanoma: North American Intergroup E1609 – Journal of Clinical Oncology (link to abstract – $ for full-text)

 


Guidelines for Diagnosis, Management, Treatment and Prevention of DRESS syndrome

17 Jan, 2020 | 09:43h | UTC

Spanish Guidelines for Diagnosis, Management, Treatment and Prevention of DRESS syndrome – Journal of Investigational Allergology and Clinical Immunology (free PDF)

 


European Consensus-based Interdisciplinary Guideline for Melanoma

17 Jan, 2020 | 02:50h | UTC

European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics – Update 2019 – European Journal of Cancer (free)

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment – Update 2019 – European Journal of Cancer (free)

 


Randomized Trial: A Head-to-head Comparison of the Efficacy and Safety of Ixekizumab and Adalimumab in Biological-naïve Patients with Active Psoriatic Arthritis

14 Jan, 2020 | 00:02h | UTC

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial – Annals of Rheumatic Diseases (free)

Commentary: We Have a Winner: Head-to-Head Study Compares Biologics for PsA – MedPage Today (free registration required)

 


Stay Updated in Your Specialty

 

No spam, just news.